Invasive fungal infection - Revision history

Aidan: /* Microbiology */

2025-12-29T19:31:27Z

Microbiology

← Older revision		Revision as of 19:31, 29 December 2025
Line 17:		Line 17:
	**[[Paracoccidioidomycosis]]		**[[Paracoccidioidomycosis]]
	**[[Sporotrichosis]]		**[[Sporotrichosis]]
	**''[[Penicillium marneffei]]''		**[[Penicillium]], including [[Penicillium marneffei]]

	===Epidemiology===		===Epidemiology===

Aidan: /* Endemic Mycoses */

2024-03-07T21:08:25Z

Endemic Mycoses

← Older revision		Revision as of 21:08, 7 March 2024
Line 129:		Line 129:
	**Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen		**Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen

	====[[Endemic Mycoses]]====		====[[Endemic mycoses\|Endemic Mycoses]]====

	*'''Host factors'''		*'''Host factors'''

Aidan at 14:50, 1 March 2024

2024-03-01T14:50:37Z

← Older revision		Revision as of 14:50, 1 March 2024
Line 161:		Line 161:
	*Only cases with at least one host factor and at least one clinical evidence, but ''without'' supporting mycological evidence		*Only cases with at least one host factor and at least one clinical evidence, but ''without'' supporting mycological evidence
	*Not used for endemic fungi		*Not used for endemic fungi

			== Further Reading ==

			* Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. ''Clin Infect Dis''. 2020 Sep 12;71(6):1367-1376. doi: [https://doi.org/10.1093/cid/ciz1008 10.1093/cid/ciz1008]. PMID: [https://pubmed.ncbi.nlm.nih.gov/31802125/ 31802125]; PMCID: [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7486838/ PMC7486838].

	[[Category:Infectious syndromes]]		[[Category:Infectious syndromes]]

Aidan at 14:49, 1 March 2024

2024-03-01T14:49:23Z

← Older revision		Revision as of 14:49, 1 March 2024
Line 28:		Line 28:
	*It excludes endemic fungi		*It excludes endemic fungi

	===Invasive ~~pulmonary~~ ~~mold~~ ~~disease~~===		===Invasive Pulmonary Mold Disease===

	*Interpretation		*Interpretation
Line 44:		Line 44:
	**Acute '''graft-versus-host disease''' grade III or IV, involving gut, lungs, or liver, which is refractory to first-line steroids		**Acute '''graft-versus-host disease''' grade III or IV, involving gut, lungs, or liver, which is refractory to first-line steroids
	*'''Clinical features'''		*'''Clinical features'''
	**'''Pulmonary aspergillosis''': any of the following patterns on CT		**'''[[Pulmonary aspergillosis]]''': any of the following patterns on CT
	***Dense, well-circumscribed lesions with or without a halo sign		***Dense, well-circumscribed lesions with or without a halo sign
	***Air crescent sign		***Air crescent sign
Line 69:		Line 69:
	***Mold on culture or microscopy of sinus aspirate		***Mold on culture or microscopy of sinus aspirate
	**For [[Aspergillus]]		**For [[Aspergillus]]
	***Galactomannan in plasma, serum, BAL, or CSF		***[[Galactomannan]] in plasma, serum, BAL, or CSF
	****Serum or plasma ≥1		****Serum or plasma ≥1
	****BAL ≥1		****BAL ≥1
Line 79:		Line 79:
	****At least 1 positive from plasma, serum, or whole blood and one positive from BAL		****At least 1 positive from plasma, serum, or whole blood and one positive from BAL

	===Other ~~probable~~ ~~invasive diseases~~===		===Other Invasive Fungi===
	====Candidiasis====		====[[Candidiasis]]====

	*'''Host factors'''		*'''Host factors'''
Line 99:		Line 99:
	**Positive T2Candida		**Positive T2Candida

	====~~Cryptococcocis~~====		====[[Cryptococcosis]]====

	*'''Host factors'''		*'''Host factors'''
Line 115:		Line 115:
	**Recovery of Cryptococcus from a specimen obtained from any nonsterile site		**Recovery of Cryptococcus from a specimen obtained from any nonsterile site

	====Pneumocystosis====		====[[Pneumocystosis]]====

	*'''Host factors'''		*'''Host factors'''
Line 129:		Line 129:
	**Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen		**Detection of Pneumocystis jirovecii DNA by quantitative real-time polymerase chain reaction in a respiratory tract specimen

	====Endemic ~~mycoses~~====		====[[Endemic Mycoses]]====

	*'''Host factors'''		*'''Host factors'''

Aidan: Text replacement - " species]]" to "]]"

2022-01-28T18:32:16Z

Text replacement - " species]]" to "]]"

← Older revision		Revision as of 18:32, 28 January 2022
Line 3:		Line 3:

	*Molds		*Molds
	**[[Aspergillus ~~species~~]]		**[[Aspergillus]]
	**[[Zygomycosis]]		**[[Zygomycosis]]
	**[[Fusarium]]		**[[Fusarium]]
Line 64:		Line 64:
	***Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)		***Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
	**'''Tracheobronchitis'''		**'''Tracheobronchitis'''
	***[[Aspergillus ~~species~~]] on BAL or bronchial brush culture		***[[Aspergillus]] on BAL or bronchial brush culture
	***Microscopy showing fungal elements on BAL or bronchial brush		***Microscopy showing fungal elements on BAL or bronchial brush
	**Sinonasal disease		**Sinonasal disease
	***Mold on culture or microscopy of sinus aspirate		***Mold on culture or microscopy of sinus aspirate
	**For [[Aspergillus ~~species~~]]		**For [[Aspergillus]]
	***Galactomannan in plasma, serum, BAL, or CSF		***Galactomannan in plasma, serum, BAL, or CSF
	****Serum or plasma ≥1		****Serum or plasma ≥1
Line 146:		Line 146:
	**[[Aspergillus]] in culture		**[[Aspergillus]] in culture
	**[[Histoplasma capsulatum]]: intracellular budding yeasts		**[[Histoplasma capsulatum]]: intracellular budding yeasts
	**[[Coccidioides ~~species~~]]: spherules		**[[Coccidioides]]: spherules
	**[[Paracoccidioides brasiliensis]]: large yeasts with multiple daughter yeasts in a “pilot-wheel configuration”		**[[Paracoccidioides brasiliensis]]: large yeasts with multiple daughter yeasts in a “pilot-wheel configuration”
	**[[Blastomyces dermatitidis]]: thick-walled, broad-based budding yeasts		**[[Blastomyces dermatitidis]]: thick-walled, broad-based budding yeasts

Aidan: /* Invasive pulmonary mold disease */

2021-01-18T21:17:51Z

Invasive pulmonary mold disease

← Older revision		Revision as of 21:17, 18 January 2021
Line 30:		Line 30:
	===Invasive pulmonary mold disease===		===Invasive pulmonary mold disease===

			*Interpretation
			**'''Possible''' IFD requires a host factor and a clinical feature, without mycological evidence
			**'''Probable''' IFD requires the presence of at least 1 host factor, a clinical feature, and mycologic evidence, and is relevant for immunocompromised patients only
			**'''Proven''' IFD is based on histopathology and can apply to any patient, regardless of whether the patient is immunocompromised
	*'''Host factors'''		*'''Host factors'''
	**Recent history of '''neutropenia''' (<0.5 × 109 neutrophils/L for >10 days) temporally related to the onset of fungal disease		**Recent history of '''neutropenia''' (<0.5 × 109 neutrophils/L for >10 days) temporally related to the onset of fungal disease

Aidan: /* Classification (excluding endemic fungi) */

2020-09-04T01:10:30Z

Classification (excluding endemic fungi)

Show changes

Aidan: /* Invasive pulmonary mold disease */

2020-06-18T13:12:17Z

Invasive pulmonary mold disease

← Older revision		Revision as of 13:12, 18 June 2020
Line 42:		Line 42:
	** '''Other pulmonary mold disease''': as above, but also including a reverse halo sign		** '''Other pulmonary mold disease''': as above, but also including a reverse halo sign
	** '''Tracheobronchitis''': tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis		** '''Tracheobronchitis''': tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
	** '''Sinonasal infection''':		** '''Sinonasal infection''':
	*** ~~Acute~~ localized pain (including pain radiating to the eye)		*** Acute localized pain (including pain radiating to the eye)
	*** ~~Nasal~~ ulcer with black eschar		*** Nasal ulcer with black eschar
	*** ~~Extension~~ from the paranasal sinus across bony barriers, including into the orbit		*** Extension from the paranasal sinus across bony barriers, including into the orbit
	** '''CNS infection''': 1 of the following 2 signs		** '''CNS infection''': 1 of the following 2 signs
	*** ~~Focal~~ lesions on imaging		*** Focal lesions on imaging
	*** ~~Meningeal~~ enhancement on MRI or CT		*** Meningeal enhancement on MRI or CT
	* '''Mycological evidence'''		* '''Mycological evidence'''
	** '''Direct test''' (cytology, direct microscopy, or culture)		** '''Direct test''' (cytology, direct microscopy, or culture)
	*** ~~Mold~~ in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:		*** Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
	*** ~~Presence~~ of fungal elements indicating a mold		*** Presence of fungal elements indicating a mold
	*** ~~Recovery~~ by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)		*** Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
	** '''Tracheobronchitis'''		** '''Tracheobronchitis'''
	*** [[Aspergillus species]] on BAL or bronchial brush culture		*** [[Aspergillus species]] on BAL or bronchial brush culture

Aidan: /* Microbiology */

2019-12-19T04:56:54Z

Microbiology

← Older revision		Revision as of 04:56, 19 December 2019
Line 9:		Line 9:
	** [[Candida]]		** [[Candida]]
	** [[Cryptococcus]]		** [[Cryptococcus]]
	*** Excludes [[Pneumocystis]]		** Excludes [[Pneumocystis]]
	* Endemic fungi		* Endemic fungi
	** [[Histoplasmosis]]		** [[Histoplasmosis]]

Aidan at 04:56, 19 December 2019

2019-12-19T04:56:36Z

@@ Line 1: / Line 1: @@
-== Microbiology ==
+== Background ==
 * Endemic fungi
 ** [[Histoplasmosis]]
@@ Line 8: / Line 17: @@
 ** [[Sporotrichosis]]
 ** ''[[Penicillium marneffei]]''
 * Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection [[CiteRef::cornely2007po]]